CHERRY HILL, N.J., May 27, 2025 (GLOBE NEWSWIRE) — Recent findings from digital marketing agency Sagapixel reveal a significant **shift in search behavior**: the term “GLP-1” has officially surpassed search volume for “Ozempic”. This is a pivotal change that highlights how patients are increasingly discovering and researching weight loss medications.
More Than Just a Trend: The Numbers Tell a Story
As of Q1 2025, searches for “GLP-1” have exceeded a staggering **3 million monthly queries**, marking a decline from Ozempic’s peak of **6 million searches** in early 2024. This transformation indicates a more informed consumer landscape, where individuals are not only knowledgeable about specific drugs but are making comparisons across a category of medications.
The Voice of Authority
Frank Olivo, CEO of Sagapixel, emphasizes this trend: “Patients are evolving; they are moving away from inquiring about Ozempic specifically to exploring GLP-1 medications as an entire class.” This shift is paving the way for healthcare providers to rethink how they market and educate patients about weight loss treatments.
Legal Factors Driving Change
The push towards the term “GLP-1” isn’t purely organic. Sagapixel has urged its clients to **remove mentions of “semaglutide”** from their platforms due to mounting legal pressures from Novo Nordisk. The challenge of ranking for a keyword that consumers actively seek has prompted a strategic pivot.
“This was a significant concern,” Olivo remarked. “With the rise of ‘GLP-1’ as a safer, high-volume keyword, providers can still connect with patients without legal pitfalls.”
Unpacking the Surge in GLP-1 Searches
So, what’s fueling this newfound interest in GLP-1? Sagapixel identifies several key drivers:
- Mass Media Advertising: Companies like Hims and Ro are spending heavily on marketing initiatives, with Hims reportedly allocating nearly **50% of its revenue** to promote its products.
- Social Media Influence: Wellness influencers and features in prominent outlets such as Vogue, Men’s Health, and The New York Times are bringing GLP-1 into the spotlight.
- Consumer Confusion: With a variety of options like Zepbound and tirzepatide, many are searching for the “**Best GLP-1 for weight loss**.”
- Clinic-Level Marketing: Providers are now shifting their services to focus on GLP-1 weight loss programs rather than brand-specific messaging.
Strategies for Providers
In light of these changes, Sagapixel advises healthcare providers to adapt swiftly:
- Embrace GLP-1 Messaging: Shift away from brand-specific content and focus on class-level information.
- Optimize for SEO: Tailor your search engine strategy around terms like “GLP-1 injections near me” to attract more traffic.
- Produce Educational Content: Create compliant resources that demonstrate your practice as a leader in navigating the evolving landscape of weight loss medications.
“This isn’t merely a marketing trend—it’s a sign that patients are more educated and expect higher standards,” Olivo highlights. “Providers who adapt to this new language will cultivate trust and see accelerated growth.”
Conclusion
As the landscape of weight loss medication continues to evolve, the shift from Ozempic to GLP-1 presents both challenges and opportunities. By embracing these changes, healthcare providers can position themselves as trusted resources for patients eager for information. The future looks promising for those who can navigate this new terrain with agility and insight.
Contact:
Shannon Dillon
[email protected]
sagapixel.com
